Disc Medicine Entered into an Exclusive License Agreement with Mabwell Therapeutics for Anti-TMPRSS6 Monoclonal Antibodies
- Mabwell will receive $10.0M up front & is also eligible to receive ~$412.5M in development and commercial milestones along with royalties on net sales
- Disc will obtain an exclusive right to develop and commercialize MWTX-003 and other novel anti-TMPRSS6 Abs (discovered by Mabwell) in the US, EU & other territories outside China and Southeast Asia. MWTX-003 showed a potent & durable suppression of serum iron and efficacy in animal models of beta-thalassemia and polycythemia vera
- Disc plans to initiate a P-I study of MWTX-003 in healthy volunteers in H2’23. Evidence from both clinical and non-clinical studies suggests that inhibiting TMPRSS6 may help treat hematologic disorders by lowering iron levels
Ref: Globenewswire | Image: Disc Medicine
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.